Tiziana's Nasal Foralumab Shows Biomarker Promise in Progressive MS
Event summary
- Tiziana's nasal foralumab reduced microglial activation in na-SPMS patients, per PET scans and CSF proteomics data.
- 10 patients in an open-label expanded-access program showed downregulation of inflammatory biomarkers and upregulation of neuroprotective proteins.
- Strong correlations observed between PET signals and CSF proteomic shifts, suggesting mechanistic link to disease modification.
- Phase 2a trial (NCT06292923) in na-SPMS ongoing, with top-line data expected in H1 2026.
The big picture
Tiziana's data suggests nasal foralumab may address unmet needs in progressive MS by targeting microglial activation without systemic immunosuppression. The results strengthen the case for intranasal immunotherapy as a differentiated approach in neuroinflammatory diseases. Success in this niche could validate Tiziana's platform technology for broader applications.
What we're watching
- Clinical Validation
- Whether the Phase 2a trial results will confirm these biomarker findings and support regulatory path.
- Differentiation Strategy
- How Tiziana positions nasal foralumab against existing MS therapies lacking neuroprotective effects.
- Pipeline Expansion
- The pace at which Tiziana advances foralumab into other neuroinflammatory indications like MSA and Alzheimer’s.
Related topics